(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 April 2011 (07.04.2011)

PCT

(10) International Publication Number
WO 2011/039358 A1

(51) International Patent Classification:
C07D 403/04 (2006.01) *C07D 417/14* (2006.01)
C07D 403/14 (2006.01) *A61K 31/427* (2006.01)
C07D 413/14 (2006.01) *A61P 3/04* (2006.01)

(21) International Application Number:
PCT/EP2010/064672

(22) International Filing Date:
1 October 2010 (01.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/247,634 1 October 2009 (01.10.2009) US

(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **XENON PHARMACEUTICALS INC.** [CA/CA]; 3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DALES, Natalie** [US/US]; Novartis Institutes for BioMedical Research, Inc., 400 Technology Square, Cambridge, Massachusetts 02139 (US). **FU, Jianmin** [US/CA]; 3170 Quintette Crescent, Coquitlam, British Columbia V3E 3B6 (CA). **JIA, Qi** [CA/CA]; 7633 Buller Avenue, Burnaby, British Columbia V5J 5M6 (CA). **POKROVSKAIA, Natalia** [CA/CA]; #202 - 335 Carnarvon Street, New Westminster, British Columbia V3L 1B9 (CA). **SUN, Shaoyi** [CA/CA]; 5-1200 Brunette Avenue, Coquitlam, British Columbia V3K 1G3 (CA). **ZHANG, Zaihui** [CA/CA]; 4038 MacDonald Street, Vancouver, British Columbia V6L 2N9 (CA).

(74) Agent: **CAMPBELL, Lachlan**; NOVARTIS PHARMA AG, Patent Department, CH-4002 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/039358 A1

(54) Title: PYRAZOLE DERIVATIVES WHICH MODULATE STEAROYL-COA DESATURASE

(57) Abstract: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.